INIGEM   23989
INSTITUTO DE INMUNOLOGIA, GENETICA Y METABOLISMO
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
Bone metabolism of ovariectomized (OVX) ewes chronically treated with high doses of zoledronic acid (ZOL): experimental model of osteonecrosis of the jaw associated to bisphosphonates (ONJBPs)
Autor/es:
DAVISON R; LYARDET L; PRELIASCO M; YAFUL G; TORRES P; PELLEGRINI G; LUGONES C; ZENI SUSANA N
Reunión:
Congreso; The 4th Joint Meeting of ECTS and IBMS; 2015
Resumen:
ONJ has emerged as a complication of bisphosphonate (BPs) treatment which induces a strong reduction in bone remodeling. Ewes could be a useful experimental model because, among others, they allow making oral cavity interventions. Objective: to evaluate the effect of high doses of ZOL (equivalent to cancer treatment) on bone remodeling and maxillary bone mass in OVX ewes. Methods: Adult Corriedale ewes?s were bilateral OVX or SHAM operated. Then, they received ZOL (n=6) or physiological solution (3 OVX and 3 SHAM). After one year (T=12) the first molar was extracted and a dental implant was done at T=24. A bone defect was done contra-laterally and calcium (Ca) and phosphorus (P) content was evaluated in the extracted material. After 4 additional months (T=28), ewes were sacrificed. Blood was drawn during all these interventions and serum Ca, P, crosslaps (CTX) and bone alkaline phosphatase (BAP) were evaluated. Hemimandible bone mineral content (BMC) was evaluated ex vivo. Results were expressed in the following order SHAM, OVX and ZOL: sCa (mg/dl): 9.1±0.8; 9.0±0.5; 8.9±0.4; sP (mg/dl): 4.63±0.21; 4.37±0.22; 3.96±0.36; BAP(mg/dl): 50.3±2.5; 58.3±0.6; 54.0±4.3; CTX; 644±8.7; 826±83*; 271±57*,**; Ca (g/g tissue): 0.707±0.263; 0.443±0.049*; 0.537±0.048*,**; P (g/g tissue): 0.290±0.084; 0.208±0.011; 0.211±0.048; BMC (g/cm2): 32.1±9.2; 24.0±6.1*; 42.3±3.0*,**. (* and **): p